Whole-Genome Sequencing Is Here, But Clinical Utility Remains Unproven
This article was originally published in The Gray Sheet
Executive Summary
Multiple firms are racing to develop an affordable whole-genome sequencing product as a marketable diagnostics tool, but clinicians and genetics experts told a government advisory panel last week that the practice is not yet ready for clinical application
You may also be interested in...
NEJM Report: Next-Gen Gene Sequencing Solves Difficult Rare Infection Case
Clinicians used unbiased next-generation gene sequencing of cerebrospinal fluid in a boy with severe immunodeficiency to discover he was infected with a rare bacterial pathogen. The case, published in the New England Journal of Medicine, suggests next-generation sequencing may help doctors treat patients with diseases that cannot be identified through conventional testing, researchers say.
IBM Edges Toward A Bargain DNA Sequencer, With Dx Applications In Sights
Computer and IT systems giant IBM is joining the race for a cheaper, faster DNA sequencing tool with its early-stage "DNA transistor" device
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.